(AZN)
NYQ – Real Time Price. Currency in USD
188.42
+5.02 (2.74%)
At close: Mar 27, 2026, 4:00 PM EDT
189.05
+0.63 (0.33%)
After-hours: Mar 27, 2026, 7:56 PM EDT
Get all premium features to the best stock analysis tool
NYQ – Real Time Price. Currency in USD
188.42
+5.02 (2.74%)
At close: Mar 27, 2026, 4:00 PM EDT
189.05
+0.63 (0.33%)
After-hours: Mar 27, 2026, 7:56 PM EDT
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
| Name | Position |
|---|---|
| Dr. Aradhana Sarin M.D. | CFO & Executive Director |
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit |
| Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology R&D |
| Mr. David Fredrickson | Executive Vice-President of Oncology Haematology Business Unit |
| Mr. Jeffrey Pott J.D. | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board |
| Mr. Joris Silon | Head of Investor Relations |
| Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | CEO & Executive Director |
| Date | Type | Document |
|---|---|---|
| 2026-03-16 | 6-K | a7541w.htm |
| 2026-03-10 | 6-K | a0663w.htm |
| 2026-03-06 | 6-K | a6797v.htm |
| 2026-03-03 | 8-A12B | tm267648d1_8a12b.htm |
| 2026-03-02 | 6-K | a7886u.htm |
| 2026-02-02 | S-8 | tm264269d1_s8.htm |
| 2026-01-30 | 25 | tm264197d1_25.htm |
| 2026-01-29 | 6-K | a9169q.htm |
| 2026-01-22 | 8-A12B | tm263731d2_8a12b.htm |
| 2026-01-20 | 6-K | a4875p.htm |
| Ms. Iskra Reic | Executive Vice President of International |
| Ms. Pam P. Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board |
| Ms. Ruth March | Senior VP of Precision Medicine - R&D Oncology |